Home › Female Infertility › NCT06701071
Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation
Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation in Patients With Diminished Ovarian Reserve Undergoing In-vitro Fertilization: a Randomized Controlled Trial
Who can join
Ages 18 to 44 · Women
Full eligibility criteria
Inclusion Criteria: * Undergoing IVF * Must meet POSEIDON criteria based on clinic evaluation * Female partner: Antral follicle count of 2 or more and age \<45 at time of stimulation start * Male partner/sperm source: Cannot be azoospermic * Planning freeze-all cycle (regardless of blastocyst or cleavage stage culture) or fresh transfer if randomized to short Clomid group * Planning 36-hour trigger window Exclusion Criteria: * Normal ovarian reserve or good response * Allergy or adverse reaction to Clomid * Minimal stimulation protocols * History of prior premature ovulation
About the study
The goal of this clinical trial is to evaluate a long Clomid protocol as compared to a 5-day Clomid protocol for ovarian stimulation in patients with diminished ovarian reserve undergoing ovarian stimulation for in-vitro fertilization. The aim of the long Clomid protocol is to intensify stimulation of the ovaries and reduce both cost and injection burden for patients. Participants will be randomized to receive the long Clomid protocol vs. the typical protocol involving Clomid only for 5 days followed by growth hormone-releasing hormone (GnRH) antagonist. The primary outcome the investigators will evaluate will be the number of mature eggs retrieved.
What is being tested
- Clomiphene Citrate (drug)
Sponsor: University of Southern California · Participants: 120 · Started: Jun 1, 2025
Contact the study team
- Bonnie Song, MD · Phone: 323-409-3026
- Rachel Mandelbaum · Phone: 323-409-3026
Official record on ClinicalTrials.gov — NCT06701071
Locations in the U.S.
| California | HRC Fertility, Pasadena |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.